29 results on '"Smolej, Lukas"'
Search Results
2. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL
3. Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)
4. Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia
5. Single-Agent Ibrutinib Versus Real-World Treatments for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Adjusted Comparison of Resonate-2™ with Real-World Databases
6. Impact of Comorbidities and Concomitant Medications on Survival of Patients with Chronic Lymphocytic Leukemia: Analysis of an Unselected Patient Population from East Bohemia
7. Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group
8. Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial
9. Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results
10. On the road to optimized BTK inhibition in CLL
11. Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life
12. A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study
13. Rituximab and High-Dose Dexamethasone (R-dex) Is Effective In The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia
14. The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen
15. Five-Color Multiplex Real-Time PCR Technology to Detect Over 75 Recurrent Chromosomal Abnormalities in Acute Myeloid Leukemia; Benefits for Minimal Residual Disease Detection
16. The Detection of Viral Infection in Bronchoalveolar Lavage Samples Collected From Recipients of Allogeneic Haematological Stem Cell Transplantation with Pneumonia (A 3 Year Epidemiological Study 2008–2010)
17. Identification of Novel Molecular Markers for the Follow-up of Minimal Residual Disease in Hematooncological Disorders
18. Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy
19. Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
20. Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
21. Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.
22. Successful Treatment with Imatinib Mesylate Significantly Decreases Plasma Levels of Vascular Endothelial Growth Factor (VEGF) and Soluble Endoglin (sCD105) but Not Basic Fibroblast Growth Factor (bFGF) or Angiopoietin-2 (Ang-2) in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase
23. Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro
24. Angiopoietin-2 mRNA Expression Is Elevated in Chronic Lymphocytic Leukemia Patients with Poor Prognostic Features
25. Circulating Angiogenic Cytokines in Chronic Lymphocytic Leukemia: Relationship to Modern Prognostic Factors and Effect of Fludarabine-Based Treatment
26. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?
27. Bone Marrow Angiogenesis in Chronic Lymphocytic Leukemia: Relationship to Classical and Modern Prognostic Factors.
28. Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Using LNA-Modified Fluorescently Labeled Probes and Real-Time PCR Technology.
29. Rituximab Maintenance after Chemoimmunotherapy Induction in 1stand 2ndLine Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.